Chronic administration of aminoguanidine reduces vascular nitric oxide production and attenuates liver damage in bile duct-ligated rats

Liver International

Volumn 25, Issue 3, 2005, Pages 647-656

  Wei, Chang Li ^a   Hon, Wei Min ^a   Lee, Kang Hoe ^a   Khoo, Hoon Eng ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Activity; Aminoguanidine; Bile duct ligation; Liver cirrhosis; Nitric oxide; Nitric oxide synthase

Indexed keywords

AMINOGUANIDINE; CALCIUM; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATTENUATION; BILE DUCT LIGATION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER INJURY; MALE; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; RANDOMIZATION; RAT; WESTERN BLOTTING;

ANIMALS; AORTA; BILE DUCTS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GUANIDINES; LIGATION; LIVER CIRRHOSIS; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY;

EID: 20844449735     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01063.x     Document Type: Article

References (38)

1. Hobbs A J, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol 1999; 39: 191-220.
2. Wiest R, Groszmann R J. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 478-91.
3. Cahill P A, Redmond E M, Hodges R, et al. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 1996; 25: 370-8.
4. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-43.
5. Hori N, Wiest R, Groszmann R J. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology 1998; 28: 1467-73.
6. Martin P Y, Xu D L. Niederberger M, et al. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol 1996; 270: F494-9.
7. Niederberger M, Martin P Y, Gines P, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995; 109: 1624-30.
8. Ros J, Jimenez W, Lamas S, et al. Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology 1995; 21: 554-60.
9. Wei C L, Khoo H E, Lee K H, Hon W M. Differential expression and localization of nitric oxide synthases in cirrhotic livers of bile duct-ligated rats. Nitric Oxide 2002; 7: 91-102.
10. Rockey D C, Chung J J. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998; 114: 344-51.
11. Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999; 117: 1222-8.
12. Loureiro-Silva M R, Cadelina G W, Groszmann R J. Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. Am J Physiol Gastrointest Liver Physiol 2003; 284: G567-74.
13. Niederberger M, Gines P, Tsai P, et al. Increased aortic cyclic guanosine monophosphate concentration in experimental cirrhosis in rats: evidence for a role of nitric oxide in the pathogenesis of arterial vasodilation in cirrhosis. Hepatology 1995; 21: 1625-31.
14. Misko T P, Moore W M, Kasten T P, et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993; 233: 119-25.
15. Hock C E, Yin K, Yue G, Wong P Y. Effects of inhibition of nitric oxide synthase by aminoguanidine in acute endotoxemia. Am J Physiol 1997; 272: H843-50.
16. Laszlo F, Whittle B J. Actions of isoform-selective and non-selective nitric oxide synthase inhibitors on endotoxin-induced vascular leakage in rat colon. Eur J Pharmacol 1997; 334: 99-102.
17. Ridger V C, Pettipher E R, Bryant C E, Brain S D. Effect of the inducible nitric oxide synthase inhibitors aminoguanidine and L-N6-(1-iminoethyl)lysine on zymosan-induced plasma extravasation in rat skin. J Immunol 1997; 159: 383-90.
18. Wu C C, Chen S J, Szabo C, et al. Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br J Pharmacol 1995; 114: 1666-72.
19. Wei C L, Lee K H, Khoo H E, Hon W M. Expression of haemoxygenase in cirrhotic rat liver. J Pathol 2003; 199: 324-34.
20. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
21. Knodell R G, Ishak K G, Black W C, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
22. Wei C L, Hon W M, Lee K H, Khoo H E. Temporal expression of hepatic inducible nitric oxide synthase in liver cirrhosis. World J Gastroenterol 2005; 11: 362-7.
23. Pizcueta M P, Pique J M, Bosch J, et al. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992; 105: 184-90.
24. Chabot F, Mestiri H, Sabry S, et al. Role of NO in the pulmonary artery hyporeactivity to phenylephrine in experimental biliary cirrhosis. Eur Respir J 1996; 9: 560-4.
25. Ros J, Claria J, Jimenez W, et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995; 22: 915-20.
26. Pilette C, Kirstetter P, Sogni P, et al. Dose-dependent effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats. J Gastroenterol Hepatol 1996; 11: 1-6.
27. Vos T A, Gouw A S, Klok P A, et al. Differential effects of nitric oxide synthase inhibitors on endotoxin-induced liver damage in rats. Gastroenterology 1997; 113: 1323-33.
28. Liu T H, Robinson E K, Helmer K S, et al. Does upregulation of inducible nitric oxide synthase play a role in hepatic injury? Shock 2002; 18: 549-54.
29. Corbett J A, Tilton R G, Chang K, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992; 41: 552-6.
30. Tsugawa K, Hashizume M, Migou S, et al. Role of nitric oxide and endothelin-1 in a portal hypertensive rat model. Scand J Gastroenterol 2000; 35: 1097-105.
31. Bieganski T, Kusche J, Lorenz W, et al. Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism. Biochem Biophys Acta 1983; 756: 196-203.
32. Seiler N, Bolkenius F N, Knodgen B. The influence of catabolic reactions on polyamine excretion. Biochem J 1985; 225: 219-26.
33. Ou P, Wolff S P. Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem Pharmacol 1993; 46: 1139-44.
34. Picard S, Parthasarathy S, Fruebis J, Witztum J L. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 1992; 89: 6876-80.
35. Fiorucci S, Antonelli E, Morelli O, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA 2001; 98: 8897-902.
36. Moal F, Chappard D, Wang J, et al. Fractal dimension can distinguish models and pharmacologic changes in liver fibrosis in rats. Hepatology 2002; 36: 840-9.
37. Yu Q, Shao R, Qian H S, et al. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000; 105: 741-8.
38. Van De C M, Omasta A, Janssens S, et al. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 2002; 51: 440-5.